Arno Therapeutics Enrolls First Patient In A Phase I Trial To Evaluate Lead Compound Onapristone In Progesterone Receptor Positive Solid Tumors

Published: Jan 22, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors. The Phase I trial is designed to identify the recommended Phase II dose and determine the overall safety profile of onapristone.

Help employers find you! Check out all the jobs and post your resume.

Back to news